Berlin, Germany
Berlin, Germany

Time filter

Source Type

A Liquid Biopsy, also known as Fluid Biopsy is the Sampling and Analysis of Non-Solid Biological Tissue, Primarily Blood. Like traditional biopsy this type of technique is mainly used as a Diagnostic and monitoring tool for diseases such as Cancer, with the added benefit of being largely non-invasive. With their unique quality of simplifying the Market Study Reports, “Market Research Future” presents a Brilliant study Report on the “Global Liquid Biopsy Market” Empowering you to browse through the full Market Analysis, Opportunities, Price, Growth, Trends and the market forecast up to the year 2022 Global Liquid Biopsy Market Report has been segmented on the basis of Therapeutic Area which comprises of Bladder cancer, Lung cancer, Brain cancer, Melanoma, Breast cancer, Non-Hodgkin lymphoma and others. On the basis of application the market is segmented into cancer Drug Development, Device Development, detection of Genetic Alterations in Tumors, cfDNA and others. On the basis of end user, market is segmented into Pharmaceutical Companies, Hospital/Clinics, Reference Laboratories, Research Institutes and others. Globally the market for Liquid Biopsy is expected to grow at a substantial rate during the period 2016 to 2022. Applications for Liquid Biopsy are expected to Witness Significant market development over the coming decade. Brain Cancer holds the largest share of the market. Some of the Key Players in this Market are: Myriad Genetics, F. Hoffmann-La Roche Ltd, QIAGEN, Biocept Inc., Trovagene, Inc, Genomic Health, RainDance Technologies, Inc, Bio-Rad Laboratories, Inc., Janssen Global Services, LLC, and others. The Report is advantageous mainly to the following Entities • Biotechnology Companies • Research Institutes • Research and Development (R&D) Companies • Liquid biopsy market service providers • Government Research Laboratories • Contract Research Organizations • Research and Consulting Companies • Liquid Biopsy Product Manufacturers and Distributors • Pharmaceutical Companies Access the market data and market information presented through more than 50 market data tables and 25 figures spread over 85 numbers of pages of the project report “Liquid biopsy Market –Forecast to 2022” Depending on geographic region, Liquid biopsy market is segmented into four key regions: Americas, Europe, Asia Pacific, and Middle East & Africa. Globally developed countries led by North America are the largest market for Liquid biopsy. Europe is the second-largest market for liquid biopsy. The developing regions market such as Asia pacific region and Middle East & Africa however is rising much faster. • Provides detailed analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the Liquid Biopsy Market • Offers insights about factors affecting the market growth • Enables to analyze the market based on various factors- Price Analysis, Supply Chain Analysis, Porters Five Force Analysis etc. • Provides historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa. • Offers country level analysis of the market with respect to the current market size and future prospective At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members. For more information, please visit https://www.marketresearchfuture.com


News Article | May 9, 2017
Site: globenewswire.com

MIAMI, May 09, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), reports operating and financial results for the three months ended March 31, 2017. OPKO’s senior management will provide a business update and discuss results in greater detail  in a conference call and live audio webcast at 4:30 p.m. Eastern time today. The conference call dial in information is listed below. To access the webcast, please log on to the OPKO website at www.opko.com. For those unable to participate in the live conference call or webcast, a replay will be available beginning May 9, 2017 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 17226044.  The replay can be accessed for a period of time on OPKO’s website at http://investor.opko.com. OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and OPK88003, an androgen receptor modulator for androgen deficiency indications. Our biologics business includes hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia in phase 2a. We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at www.opko.com. This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected financial performance and expectations regarding sales of our products, whether 4Kscore test utilization will continue to grow, our product development efforts and the expected benefits of our products, including whether our ongoing and future clinical trials will be successfully completed on a timely basis or at all and whether the data from any of our trials will support approval, validation and/or reimbursement for our products, the expected timing for launch of our products in development, whether the data for the hGH-CTP study in adults will support approval of a BLA, the expected timing of commencing and concluding our clinical trials, enrollment in clinical trials, and disclosure of results for the trials, the timing of our regulatory submissions, our ability to market and sell any of our products in development, expectations about developing RAYALDEE for dialysis patients, our ability to obtain broad reimbursement coverage for the 4Kscore test, increased adoption rates for the 4Kscore, the recommendations expected for the KDIGO guidelines, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission, as well as integration challenges for Bio-Reference, EirGen, Transition, and other acquired businesses, the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, that earlier clinical results of effectiveness and safety may not be reproducible or indicative of future results, that the 4Kscore, RAYALDEE, Varubi™, hGH-CTP, OPKO88003, OPK88004, and/or any of our compounds or diagnostic products under development may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications, that currently available over-the-counter and prescription products, as well as products under development by others, may prove to be as or more effective than our products for the indications being studied. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions, government investigations and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.


News Article | May 9, 2017
Site: globenewswire.com

MIAMI, May 09, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), reports operating and financial results for the three months ended March 31, 2017. OPKO’s senior management will provide a business update and discuss results in greater detail  in a conference call and live audio webcast at 4:30 p.m. Eastern time today. The conference call dial in information is listed below. To access the webcast, please log on to the OPKO website at www.opko.com. For those unable to participate in the live conference call or webcast, a replay will be available beginning May 9, 2017 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 17226044.  The replay can be accessed for a period of time on OPKO’s website at http://investor.opko.com. OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and OPK88003, an androgen receptor modulator for androgen deficiency indications. Our biologics business includes hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia in phase 2a. We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at www.opko.com. This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected financial performance and expectations regarding sales of our products, whether 4Kscore test utilization will continue to grow, our product development efforts and the expected benefits of our products, including whether our ongoing and future clinical trials will be successfully completed on a timely basis or at all and whether the data from any of our trials will support approval, validation and/or reimbursement for our products, the expected timing for launch of our products in development, whether the data for the hGH-CTP study in adults will support approval of a BLA, the expected timing of commencing and concluding our clinical trials, enrollment in clinical trials, and disclosure of results for the trials, the timing of our regulatory submissions, our ability to market and sell any of our products in development, expectations about developing RAYALDEE for dialysis patients, our ability to obtain broad reimbursement coverage for the 4Kscore test, increased adoption rates for the 4Kscore, the recommendations expected for the KDIGO guidelines, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission, as well as integration challenges for Bio-Reference, EirGen, Transition, and other acquired businesses, the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, that earlier clinical results of effectiveness and safety may not be reproducible or indicative of future results, that the 4Kscore, RAYALDEE, Varubi™, hGH-CTP, OPKO88003, OPK88004, and/or any of our compounds or diagnostic products under development may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications, that currently available over-the-counter and prescription products, as well as products under development by others, may prove to be as or more effective than our products for the indications being studied. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions, government investigations and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.


What's the Size of the Clinical Laboratory Market in Several Country Markets? Global Laboratory Market: by-Country Market Analysis (U.S., China, Japan, Germany, France, Spain, Italy, Brazil, EMEA and others) provides an overview of the clinical laboratory industry and the trends driving growth. Market data presented include the following: Internationally, the clinical laboratory market is growing. Clinical Laboratory Services Market presents information as a global focused market report. Key regions discussed include Northern America; Europe, Middle East, and Africa (EMEA); Asia Pacific; and Latin America. Datasets provided include the following: - Estimated U.S. Laboratory Service Revenues and Market Share of Leading Clinical Laboratory Providers, 2016 - Estimated U.S. Laboratory Service Revenues for Leading Clinical Laboratory Providers, 2010 vs. 2016 Trends and Issues discussed in this report are inclusive of population statistics,  disease statistics, new issues, regulatory environment, laboratory regulation, reimbursement, payer types, and developments in personalized medicine. The clinical laboratory market is highly competitive in terms of prices, locations, and services offered. Larger laboratories have advantages in the market due to the wide exposure, large number of locations, and greater financial positions. The report profiles companies that are the leaders in the industry, including: 3: Issues And Trends In The Clinical Laboratory Industry - Certificate of Compliance and Certificate of Accreditation - ALERE, Inc - Bio-Reference Laboratories - OPKO - Davita Healthcare Partners, Inc. - Genomic Health, Inc. - Genomic Health, Inc. - Laboratory Corporation of America - Myriad Genetics, Inc. - Neogenomics, Inc. - Quest Diagnostics, Inc. - Siemens Healthineers - Sonic Healthcare Limited - Spectra Laboratories: A Fresenius Company - Synlab International Gmbh For more information about this report visit http://www.researchandmarkets.com/research/m9hsjn/global_clinical Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-clinical-laboratory-market-analysis-2010-2021-market-leaders-are-quest-diagnostics-bio-reference-laboratories-opko-genomic-health-laboratory-corporation-of-america--myriad-genetics-300462442.html


News Article | May 8, 2017
Site: globenewswire.com

MIAMI, May 08, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company, will announce operating and financial results for the three months ended March 31, 2017, after the close of the U.S. financial markets on Tuesday, May 9, 2017. OPKO’s senior management will provide a business update and discuss its financial results in a conference call and live audio webcast beginning at 4:30 p.m. Eastern time on Tuesday, May 9, 2017. For those unable to participate in the live conference call or webcast, a replay will be available beginning May 9, 2017 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 17226044. The replay can be accessed for a period of time on OPKO’s website at http://investor.opko.com/events.cfm. About OPKO Health, Inc. OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation’s third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), TT401, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and TT701, an androgen receptor modulator for androgen deficiency indications. Our biologics business includes hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), a long-acting oxyntomodulin for diabetes and obesity (in Phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at www.opko.com.


News Article | May 1, 2017
Site: www.marketwired.com

ALBUQUERQUE, NM--(Marketwired - May 01, 2017) - TriCore Reference Laboratories' CEO Khosrow Shotorbani will be a keynote speaker at this week's Executive War College on Laboratory and Pathology Management in New Orleans, Louisiana. The international conference showcases innovations by leading laboratory organizations worldwide and helps laboratory administrators and pathologists learn practical methods for improving the performance and financial success of their laboratories. Shotorbani will speak at a general session on Tuesday, May 2, on the future of clinical lab services and opportunities for labs to prosper in the future state of healthcare. Shotorbani will provide insights on how TriCore is developing and providing enriched lab services that add new value for physicians, payers and, ultimately, patients in New Mexico. Shotorbani said, "TriCore and New Mexico are serving as an incubator for the future clinical laboratory business model, reshaping the way healthcare is delivered. I am proud to share our story on the international stage." TriCore representatives, Shotorbani as well as VP of IT, Aron Seidman, and members of the Enterprise Clinical Solutions team, Kathleen Swanson and Monique Dodd, will also present in a full-day, post-conference workshop on Clinical Lab 2.0 as part of Project Santa Fe. Project Santa Fe includes leaders from five clinical laboratory operations across the country: Henry Ford Health System, Geisinger Health System, Kaiser Permanente Northern California Health Systems, Northwell Health Laboratories, and TriCore Reference Laboratories. The coalition was established both to provide thought leadership and to help develop the evidence base for the valuation of clinical laboratory services in the next era of American healthcare. TriCore Reference Laboratories is a clinical reference laboratory founded and headquartered in Albuquerque, NM that provides over 1,700 full-service, state-of-the-art laboratory tests to health care professionals and their patients. TriCore also provides investigational services including FDA-regulated clinical trials, IRB-approved studies, and instrument testing. For more information, visit tricore.org. For more information on the Executive War College visit executivewarcollege.com


News Article | April 13, 2017
Site: globenewswire.com

ALBUQUERQUE, N.M., April 13, 2017 (GLOBE NEWSWIRE) -- The Albuquerque March of Dimes has named TriCore Reference Laboratories' Chief Administration Officer, Dr. Nick Dayan, as the 2017/2018 Chair of the Albuquerque March for Babies. TriCore is also the signature sponsor of this year's event. Dr. Dayan said of being chosen the Chair of the event, "I am so honored to be named the Chair of this marvelous event. By supporting the March for Babies program, we as a community have the ability to affect our newborns for a lifetime." The March for Babies will be held on Saturday, May 6, 2017 at Johnson Field on the UNM Campus. Registration will be at 10:00AM and the walk starts at 11:30AM. Please go to: bit.ly/marchforbabiesABQ for more information or to register to be a participant. Nearly 4 million babies are born annually in the US. All babies, whether they are born early or on time benefit from advances in prenatal and postpartum care made possible by the March of Dimes. Since 1970, March for Babies has been the biggest fundraiser for the March of Dimes in Albuquerque – last year's event raised $169,000 with the donations going to support the March of Dimes local efforts as well as support the five national Prematurity Research Centers. Lori Medik, Executive Director of Market Development for the March of Dimes, stated, "March for Babies is an incredible community event that allows us to focus attention on prematurity, birth defects, and infant mortality. Annually, in New Mexico 25,800 babies are born. Of these babies, 2,448 are born preterm, 782 are born with a birth defect, and 139 die before reaching their first birthday. While not everyone has a direct mission connection, everyone is affected by prematurity, birth defects, and infant mortality. Preterm birth alones costs our state $126 million a year, approximately $26 billion nationally. We care about all babies and March for Babies is an opportunity for each of us to make a difference." About March of Dimes The March of Dimes is the leading nonprofit organization for pregnancy and baby health. For more than 75 years, moms and babies have benefited from March of Dimes research, education, vaccines, and breakthroughs. About TriCore Reference Laboratories TriCore Reference Laboratories is a clinical reference laboratory providing a complete range of services to health care professionals across the Southwest as well as pathology consultation services to clinicians across the country. For more information, visit www.tricore.org


News Article | February 27, 2017
Site: globenewswire.com

MIAMI, Feb. 27, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company, will announce operating and financial results for the fourth quarter ended December 31, 2016 after the close of the U.S. financial markets on Wednesday, March 1, 2017. OPKO’s senior management will provide a business update and discuss its financial results in a conference call and live audio webcast beginning at 4:30 p.m. Eastern time on Wednesday, March 1, 2017. For those unable to participate in the live conference call or webcast, a replay will be available beginning March 1, 2017 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 80392791. The replay can be accessed for a period of time on OPKO’s website at http://investor.opko.com/events.cfm. About OPKO Health, Inc. OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation’s third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), TT401, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and TT701, an androgen receptor modulator for androgen deficiency indications. Our biologics business includes hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), a long-acting oxyntomodulin for diabetes and obesity (in Phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at www.opko.com.


News Article | March 1, 2017
Site: globenewswire.com

MIAMI, March 01, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), reports financial and operating results for the three months ended December 31, 2016. “OPKO reached a number of important milestones during 2016,” stated Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO.  “We launched RAYALDEE, the first new medicine we have developed and launched ourselves.  The commercial team is making great strides in the early days of the launch and has so far secured formulary access for 60% of all U.S. insured patients.” “Use of our innovative 4Kscore test for predicting the probability of aggressive prostate cancer increased to nearly 18,000 tests ordered in the fourth quarter.  We have now set the stage for continued, profitable growth at BioReference with a revenue cycle management program that is expected to improve financial results on an ongoing basis. “We have a number of important initiatives ahead of us in 2017 and early 2018.  We will complete the recently initiated clinical trial for our Claros POC diagnostic test for PSA and plan to file a PMA as quickly as possible upon completion.  Along with our partner, Vifor Fresenius, we plan to initiate a Phase 2 trial in dialysis patients with SHPT.  We also plan to initiate a Phase 2b trial for our SARM for the treatment of BPH, a condition that affects approximately 50 million men in the U.S., as well as a Phase 2 dose escalation study for TT401 to treat obesity and type II diabetes. “We are diligently working to complete analysis of the data from our Phase 3 clinical trial for hGH-CTP in adults and are aggressively advancing our pediatric Phase 3 clinical trial for hGH-CTP,” Dr. Frost concluded. OPKO’s senior management will provide a business update and discuss the results in greater detail  in a conference call and live audio webcast at 4:30 p.m. Eastern time today. The conference call dial in information is listed below. To access the webcast, please log on to the OPKO website at www.opko.com. For those unable to participate in the live conference call or webcast, a replay will be available beginning March 1, 2017 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 80392791. The replay can be accessed for a period of time on OPKO’s website at http://investor.opko.com/events.cfm. OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), TT401, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and TT701, an androgen receptor modulator to treat men with BPH. Our biologics portfolio includes hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia (in phase 2a). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information available at www.opko.com. This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected financial performance, whether we will experience continued, profitable growth at Bio-Reference, whether our revenue cycle management program will improve financial results, our product development efforts and the expected benefits of our products, including whether our ongoing and future clinical trials will be successfully completed on a timely basis or at all and whether the data from any of our trials will support approval, validation and/or reimbursement for our products, the expected timing for launch of our products in development, whether the data for the hGH-CTP study in adults will support approval of a BLA, the expected timing of commencing and concluding our clinical trials, enrollment in clinical trials, and disclosure of results for the trials, the timing of our regulatory submissions, our ability to market and sell any of our products in development, expectations about developing RAYALDEE for dialysis patients, our ability to obtain broad reimbursement coverage for the 4Kscore test, increased adoption rates for the 4Kscore, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission, as well as integration challenges for Bio-Reference, EirGen, Transition, and other acquired businesses, the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, that earlier clinical results of effectiveness and safety may not be reproducible or indicative of future results, that the 4Kscore, RAYALDEE, Varubi™, hGH-CTP, TT-401, TT-701, and/or any of our compounds or diagnostic products under development may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications, that currently available over-the-counter and prescription products, as well as products under development by others, may prove to be as or more effective than our products for the indications being studied. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.


News Article | January 23, 2017
Site: globenewswire.com

ALBUQUERQUE, N.M., Jan. 23, 2017 (GLOBE NEWSWIRE) -- When Karissa Culbreath isn't publishing articles and presenting about infectious diseases, this Scientist is actively engaged in the community and now, preparing to be on the national stage for the children's book she authored, "Daddy's Little Girl". This February Culbreath, who is the Scientific Director for Infectious Diseases at TriCore Reference Laboratories- the largest healthcare lab in New Mexico, will trade in her lab coat for an evening gown to walk the red carpet at the NAACP Image Awards. "Every little girl has dreams of what she can be when she grows up. This story highlights the role of the encouragement and affirmations of a father in building those dreams in a young girl. From doctor to architect, teacher to firefighter, girls can be anything they want to be. Reinforcement of those dreams by the words of her father has the power to positively influence her ability to achieve those goals," says Culbreath.   In addition to telling an inspirational story, "Daddy's Little Girl" also includes suggestions for encouraging those integral father-daughter chats. "The book concludes with words of affirmation and conversation starters to help to reinforce the relationship between a father and daughter," adds Culbreath.   One dad reviewed the book saying, "This book brought a tear to my eyes. I don't always know what to say to my daughter, she is just so different from me. When we read the book, and did the affirmations at the end, we started a whole new part of our relationship."   The NAACP Image Awards show will air live on Saturday, February 11, 2017 at 9/8pm Central on TV ONE.   "Daddy's Little Girl" is available on amazon . For more information about the author, visit http://karissaculbreath.com/ Photos accompanying this release are available at:

Loading Reference Laboratories collaborators
Loading Reference Laboratories collaborators